Of every medication examined in Robert J. Brent’s new economic analysis of dementia treatments, one stands out as the most damaging by a wide margin: antipsychotics.

That might not shock anyone who’s followed the headlines. The FDA has issued a “black box” warning, its strongest warning, against using antipsychotics for dementia-related symptoms. Human Rights Watch has published an entire report on the practice. And yet, prescription rates for people with dementia living in nursing homes still range from 20% to 50%. This isn’t a hidden problem. It’s a known one that persists anyway. What Brent’s research adds is a number that puts the scale of the harm in stark relief.

What the data actually shows

Antipsychotics are typically prescribed to manage agitation, aggression, or wandering in patients with dementia behaviors that, understandably, are exhausting for caregivers and nursing home staff to manage. The justification often given is that these drugs improve quality of life for the patient, even if the trade-off is some added mortality risk.

Brent’s analysis tested that justification directly, and it didn’t hold up. The medications were associated with a significant rise in dementia symptoms a jump of nearly 1.9 points on the standard clinical scale- dwarfing the effects of any other medication studied. They also came with a substantial mortality cost, both directly (side effects like sedation and cardiac risk) and indirectly (through the worsened dementia itself).

When every effect was converted into dollar terms and weighed against the roughly $63,000 lifetime cost of the medication, the total came to a net loss of about $227,000 per person, the single worst result of any intervention in the entire two-book research project.

Crucially, the “it improves quality of life” defense doesn’t survive contact with the data either. Quality-of-life effects were measured separately and came back negative, not positive. There was no offsetting benefit to weigh against the mortality cost. The justification given for the practice simply wasn’t supported.

Why does this keep happening anyway?

The book lays out three mechanisms drawn from the wider research literature, and none of them are flattering. First, people living in nursing homes are prescribed antipsychotics at far higher rates than people with dementia living at home, consistent with reports that the drugs are sometimes used as a “chemical restraint,” administered for staff convenience rather than medical necessity, often without the resident’s knowledge or consent. Second, residents in these settings are frequently already on a long list of medications, an average of seven in the sampled data, making it easy for one more prescription to go unnoticed by families. Third, antipsychotics are well known to cause weight gain, which independently raises the risk of heart attack and death.

The fines don’t fit the harm.

There’s a real regulatory response already in motion here. In 2012, the Centers for Medicare and Medicaid Services launched a national initiative specifically targeting antipsychotic overuse in nursing homes, and it worked: use among long-stay residents dropped by more than a third between 2011 and 2017. Brent’s research confirms this was a genuinely worthwhile policy, one of the clearest wins in the whole book.

But the penalties attached to violations tell a different story. Human Rights Watch found that 80% of fines for inappropriate antipsychotic prescribing came in under $10,000, with most of the rest capped at $100,000. Set against a documented harm of roughly $227,000 per person, that math doesn’t add up. A fine that’s smaller than the damage it’s meant to deter isn’t much of a deterrent.

What actually works instead

The encouraging part of this chapter isn’t just “stop the drugs”; it’s that alternatives exist and have already been tested. A person-centered program called WHELD has been shown to reduce the same agitation antipsychotics are meant to target, while actually improving quality of life and costing less than standard care. It’s proof that the choice isn’t really “sedate the patient or do nothing.” There’s a real, evidence-backed middle path; it’s just not the one that requires the least effort from an under-resourced facility.